CD8+ T-Cell Signatures as Prognostic and Immunotherapy Response Predictors in Non-Small Cell Lung Cancer.

IF 1.1 4区 医学 Q3 BIOLOGY
Tienan Zhao, Sarinder Kaur Dhillon
{"title":"CD8+ T-Cell Signatures as Prognostic and Immunotherapy Response Predictors in Non-Small Cell Lung Cancer.","authors":"Tienan Zhao, Sarinder Kaur Dhillon","doi":"10.14712/fb2024070040196","DOIUrl":null,"url":null,"abstract":"<p><p>Non-small cell lung carcinoma (NSCLC) represents the majority of lung cancer cases, comprising approximately 85 % of the total. The five-year survival rate for NSCLC patients remains discouragingly low. Recently, immunotherapy has emerged as a promising approach. Nevertheless, only a minority of patients experience considerable benefits from these treatments. This highlights the critical need for effective biomarkers that can predict both patient prognosis and response to immunotherapy. CD8+ T cells play a crucial role in cancer immunotherapy. Their presence within tumours is generally indicative of a favourable prognosis and increased efficacy of immunotherapy. This study was undertaken to identify and authenticate a novel biomarker signature based on CD8+ T-cell marker genes, to prognosticate therapeutic responses in individuals afflicted with NSCLC. This in-depth study was based on a total of 1,200 samples, which included four NSCLC specimens analysed through single-cell RNA sequencing (scRNA-seq), 1,000 NSCLC samples obtained from The Cancer Genome Atlas (TCGA) and 196 NSCLC specimens collected from the GSE37745 cohort. In patients with NSCLC, those presenting a favourable risk profile demonstrated notable elevations in specific immune cells while concurrently exhibiting reductions in other types. CD8+ T cells, with their established role in inducing apoptosis in cancer cells, have emerged as crucial predictors and modulators of treatment strategies for NSCLC patients. The combination of single-cell and bulk RNA sequencing has produced a biomarker signature, emphasizing the CD8+ T cells' crucial role in NSCLC prognosis and treatment.</p>","PeriodicalId":12281,"journal":{"name":"Folia Biologica","volume":"70 4","pages":"196-208"},"PeriodicalIF":1.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Folia Biologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14712/fb2024070040196","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Non-small cell lung carcinoma (NSCLC) represents the majority of lung cancer cases, comprising approximately 85 % of the total. The five-year survival rate for NSCLC patients remains discouragingly low. Recently, immunotherapy has emerged as a promising approach. Nevertheless, only a minority of patients experience considerable benefits from these treatments. This highlights the critical need for effective biomarkers that can predict both patient prognosis and response to immunotherapy. CD8+ T cells play a crucial role in cancer immunotherapy. Their presence within tumours is generally indicative of a favourable prognosis and increased efficacy of immunotherapy. This study was undertaken to identify and authenticate a novel biomarker signature based on CD8+ T-cell marker genes, to prognosticate therapeutic responses in individuals afflicted with NSCLC. This in-depth study was based on a total of 1,200 samples, which included four NSCLC specimens analysed through single-cell RNA sequencing (scRNA-seq), 1,000 NSCLC samples obtained from The Cancer Genome Atlas (TCGA) and 196 NSCLC specimens collected from the GSE37745 cohort. In patients with NSCLC, those presenting a favourable risk profile demonstrated notable elevations in specific immune cells while concurrently exhibiting reductions in other types. CD8+ T cells, with their established role in inducing apoptosis in cancer cells, have emerged as crucial predictors and modulators of treatment strategies for NSCLC patients. The combination of single-cell and bulk RNA sequencing has produced a biomarker signature, emphasizing the CD8+ T cells' crucial role in NSCLC prognosis and treatment.

非小细胞肺癌(NSCLC)占肺癌病例的大多数,约占总数的 85%。非小细胞肺癌患者的五年生存率仍然很低,令人沮丧。最近,免疫疗法已成为一种很有前景的方法。然而,只有少数患者能从这些治疗中获得可观的收益。这就凸显了对能预测患者预后和对免疫疗法反应的有效生物标志物的迫切需要。CD8+ T 细胞在癌症免疫疗法中起着至关重要的作用。它们出现在肿瘤中通常预示着良好的预后和免疫疗法的疗效。这项研究旨在根据 CD8+ T 细胞标记基因确定和验证一种新型生物标记特征,以预测 NSCLC 患者的治疗反应。这项深入研究基于总共1200个样本,其中包括通过单细胞RNA测序(scRNA-seq)分析的4个NSCLC样本、从癌症基因组图谱(TCGA)中获得的1000个NSCLC样本以及从GSE37745队列中收集的196个NSCLC样本。在 NSCLC 患者中,那些风险状况良好的患者表现出特定免疫细胞的明显升高,同时其他类型的免疫细胞也有所减少。CD8+ T 细胞具有诱导癌细胞凋亡的作用,已成为 NSCLC 患者治疗策略的重要预测因子和调节因子。单细胞和大量 RNA 测序的结合产生了一种生物标记特征,强调了 CD8+ T 细胞在 NSCLC 预后和治疗中的关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Folia Biologica
Folia Biologica 医学-生物学
CiteScore
1.40
自引率
0.00%
发文量
5
审稿时长
3 months
期刊介绍: Journal of Cellular and Molecular Biology publishes articles describing original research aimed at the elucidation of a wide range of questions of biology and medicine at the cellular and molecular levels. Studies on all organisms as well as on human cells and tissues are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信